Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Medicina (Kaunas). 2023 Dec 17;59(12):2190. doi: 10.3390/medicina59122190.
Phosphodiesterase type 5 (PDE5) is pivotal in cellular signalling, regulating cyclic guanosine monophosphate (cGMP) levels crucial for smooth muscle relaxation and vasodilation. By targeting cGMP for degradation, PDE5 inhibits sustained vasodilation. PDE5 operates in diverse anatomical regions, with its upregulation linked to various pathologies, including cancer and neurodegenerative diseases. Sildenafil, a selective PDE5 inhibitor, is prescribed for erectile dysfunction and pulmonary arterial hypertension. However, considering the extensive roles of PDE5, sildenafil might be useful in other pathologies. This review aims to comprehensively explore sildenafil's therapeutic potential across medicine, addressing a gap in the current literature. Recognising sildenafil's broader potential may unveil new treatment avenues, optimising existing approaches and broadening its clinical application.
磷酸二酯酶 5(PDE5)在细胞信号转导中起着关键作用,调节环鸟苷酸单磷酸(cGMP)水平,对平滑肌松弛和血管舒张至关重要。通过靶向 cGMP 进行降解,PDE5 抑制持续的血管舒张。PDE5 在不同的解剖区域发挥作用,其上调与多种病理学有关,包括癌症和神经退行性疾病。西地那非是一种选择性 PDE5 抑制剂,用于治疗勃起功能障碍和肺动脉高压。然而,鉴于 PDE5 的广泛作用,西地那非在其他病理学中可能也有一定的应用价值。本综述旨在全面探讨西地那非在医学领域的治疗潜力,填补当前文献中的空白。认识到西地那非的更广泛的应用潜力可能会开辟新的治疗途径,优化现有方法并扩大其临床应用。